The “classic” endocannabinoid (eCB) system includes the cannabinoid receptors CB1 and CB2, the eCB ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their metabolic enzymes. An emerging literature documents the “eCB deficiency syndrome” as an etiology in migraine, fibromyalgia, irritable bowel syndrome, psychological disorders, and other conditions. We performed a systematic review of clinical interventions that enhance the eCB system—ways to upregulate cannabinoid receptors, increase ligand synthesis, or inhibit ligand degradation.
Oral Cannabidiol Prevents Neurological Dysfunctions in a Mouse Model of Mild Traumatic Brain Injury
CBD Versus Nicotine
CBD may help the heart, inflammation and more…
In this study, we have investigated the effects of cannabidiol (CBD) on myocardial dysfunction, inflammation, oxidative/nitrosative stress, cell death and interrelated signaling pathways, using a…
Non-psychoactive cannabinoid may enable drug addiction recovery
Gravida feugiat nascetur adipiscing metus dolor a cum class curae cum consectetur vel in ut phasellus commodo vestibulum adipiscing nam fringilla scelerisque. Adipiscing odio ullamcorper.